Biosimilars in Retinal Diseases: A Primer

Retinal disease management has witnessed remarkable advances with the development of anti-VEGF molecules such as Lucentis® (ranibizumab), Eylea® (aflibercept), off-label bevacizumab (Avastin) and the latest molecule Brolucizumab i n the management of various retinal diseases such as diabetic macular...

Full description

Saved in:
Bibliographic Details
Main Authors: Rashmi Rawat, Rushil Kumar Saxena, Manisha Agarwal
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-04-01
Series:Delhi Journal of Ophthalmology
Subjects:
Online Access:https://journals.lww.com/10.4103/DLJO.DLJO_132_23
Tags: Add Tag
No Tags, Be the first to tag this record!